|Bid||2.6800 x 800|
|Ask||3.0400 x 1000|
|Day's Range||2.6700 - 2.7300|
|52 Week Range||2.1800 - 10.2000|
|Beta (3Y Monthly)||2.04|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
While it may not be enough for some shareholders, we think it is good to see the Mustang Bio, Inc. (NASDAQ:MBIO) share...
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
Do you remember the movie The Boy in the Plastic Bubble starring John Travolta? How about Bubble Boy starring Jake Gyllenhaal? Both were about a child born without an immune system, forced to live in a bubble to avoid contamination from the outside world.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsWell, now, Mustang Bio (NASDAQ:MBIO) has cured eight infants suffering from the "Bubble Boy" immune disorder, sending MBIO stock up as high as $10.20 in pre-Good Friday trading. The question investors are asking themselves today is whether they should get in on the action before it's too late. FOMO is alive and well and living in this micro-cap biotechnology stock. Why MBIO Stock Is a Good Speculative BetAny time a biotech company comes up with a gene therapy that works, there's bound to be excitement surrounding it. Even better if the infants suffered few, if any, side effects from the experimental gene therapy.Mustang Bio is a 2015 spinoff of Fortress Biotech (NASDAQ:FBIO), a company that is run by Lindsay Rosenwald and Michael Weiss, two serial healthcare entrepreneurs, who've spread lots of bets on small companies like Mustang Bio, of which Fortress owns approximately 38%. * 10 High-Yielding Dividend Stocks That Won't Wilt "While I am a biotech entrepreneur, I am also a 'risk manager,' as we have many shots on goal for such small companies," Rosenwald said in an email. "The more shots on goal, theoretically the less risk there is."However, despite the success of the gene therapy to date, it likely won't file for FDA approval until late 2021 or beyond. In the meantime, it's little to no money in -- 2018 income of $561,000 from interest on its cash on hand -- and $31.2 million in operating expenses, such as research and development, out. So, it's likely to burn through $100 million in operating losses before it even files with the FDA. While this might seem like an argument as to why MBIO stock is not a good speculative bet, it's counter-intuitive. Mustang Bio had cash and short-term investments of $61 million at the end of 2017. At the end of 2018, it was down to $34 million, a reduction of around $29 million, not too far off the operating losses for the year. The company announced on March 29, a $20 million venture debt financing agreement at 9% plus the amount by which the one month LIBOR rate exceeds 2.5%. It's currently at 2.48%. With interest rates stalled and possibly heading lower if a recession rears its ugly head, it looks like Mustang Bio's on the hook for about $1.8 million in interest on the loan.That gets it to $54 million on the balance sheet, close to two years worth of operating losses and into 2021. At that point, should everything about MB-107 remain positive, Mustang Bio will have plenty of financing options to get itself through the next two years, including issuing some more MBIO stock. As speculative biotech plays go, Mustang Bio seems like a good one. Why It's NotWhen it comes to biotech investing, there's no sure thing. The company still needs to confirm the benefits of a handful of patients who've received the experimental gene therapy. Those patients could fail to benefit from MB-107, as the others did. In 2020, Mustang Bio takes over the trial program from St. Jude Children's Research Hospital, which is licensing the gene therapy to the company. It's possible, but unlikely, that something could go wrong from a clinical perspective once the trial is in Mustang Bio's hands. However, CEO Manny Litchman doesn't think so. "The data are extraordinary for every single patient," Litchman said. "It's that compelling nature of the data, in particular for those who don't have a matched sibling donor, that we believe will convince the FDA to do this. Of course, just as in life, we don't always get what we want. The FDA could say no to Mustang Bio and then it's back to the drawing board after more than $150 million in losses. The Bottom Line on Mustang Bio StockI'm not a big believer in investing in money-losing companies. However, as Fortress' Rosenwald said, you've got to take a lot of shots in biotech to be successful. The same goes for biotech investing. * Verizon 5G Launch: 12 Things We Know If you can afford to lose your entire investment, I wouldn't see a problem putting down a small wager on MBIO stock. While you're at it, you might put a small amount in Fortress as well to spread your bets and all that cautionary advice. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Is Mustang Bio the Next Great Biotech Stock? appeared first on InvestorPlace.
Mustang Bio news concerning a trial about a new gene therapy for treating "bubbly boy" disease has MBIO stock soaring on Thursday.Source: Shutterstock Mustang Bio (NASDAQ:MBIO) notes that a Phase1/2 clinical trial of a gene therapy to treat XSCID, which is also known as SCID-X1. This therapy results in children not having a proper immune system and being unable to fight off illnesses.According to the Mustang Bio news release, a lentiviral gene therapy was used on infants under two years of age with the bubble boy disease. There are currently 10 infants that have gone through this therapy and the recent results come from eight of those patients.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMustang Bio has found that the lentiviral gene therapy has been a success for the eight patients tracked in the study. These eight patients saw a successful transferring of a normal copy of the IL2RG gene to bone marrow stem cells.All eight of the patients in the study have cleared their previous infections and are now growing normally. Seven of the eight saw CD3+, CD4+ and CD4+ naive T-cell and natural killer normalization within three to four months after treatment. The eighth infant initially had insufficient T cells, but has now normalized. * 5 Dividend Stocks Perfect for Retirees "The results have been very good thus far. We've been able to restore a full immune system pretty quickly," Ewelina Mamcarz, M.D., said in a statement. "All of these patients were able to come off of isolation and they've returned home with immune systems that were fully functional."MBIO stock was up 128% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Mustang Bio News: MBIO Stock Skyrockets on New 'Bubble Boy' Therapy appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Recognized as an innovator in the chimeric antigen receptor (CAR) engineered T cell (CAR-T) space, Mustang Bio (MBIO) has focused its efforts on immuno-oncology indications since its inception in 2015. The company targets both liquid and solid tumors using CAR-T and has built a facility to supply manufactured cell products for clinical trials and commercial production. Despite this emphasis and progress with MB-102, Mustang acquired an existing gene therapy program with promising clinical data and a clear path to registration via expedited pathways.